Clinical Efficacy of Silk Sericin Dressing With Collagen for Split-thickness Skin Graft Donor Site Treatment
Study Details
Study Description
Brief Summary
To examine the efficacy and safety of sericin dressing with collagen in STSG donor site treatment comparing with Bactigras®. Around 30 patients will be enrolled in this study.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Wounds are a public health problem found worldwide that associated with both clinical and economic burdens. Although several wound dressings are available, some limitations of those dressings still existed resulting in the need for new wound dressing development.
The sericin dressing with collagen was developed to provide a moist environment and bioactive ingredients to the wound bed. To evaluate its efficacy and safety, the STSG donor sites of each patient will be divided into two equal areas. Each area will be randomly allocated into sericin dressing with collagen group or control group (Bactigras®). The outcomes will be collected to examine the efficacy and safety of sericin dressing with collagen in comparison with commercial dressing Bactigras®.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Sericin dressing with collagen Sericin dressing with collagen |
Other: wound dressing application
Sericin dressing with collagen or Bactigras will be used as a primary dressing for treating the STSG donor site.
|
| Active Comparator: Bactigras Commercial dressing |
Other: wound dressing application
Sericin dressing with collagen or Bactigras will be used as a primary dressing for treating the STSG donor site.
|
Outcome Measures
Primary Outcome Measures
- Time to complete healing [42 days]
The number of days since starting treatment until the primary dressing can spontaneously detach from wound with full re-epithelialization (at least 95% re-epithelialization) without any drainage.
Secondary Outcome Measures
- Pain score [42 days]
Pain score evaluated by patient using visual analog scales (0-10)
- Incidence of infection [42 days]
The incidence of infection will be reported as "present" or "not present". Infection wound is wound which has purulent secretion or some of the inflammatory reactions (erythema, warmth, pain or tenderness, or induration) and has positive result from microbiological test.
- Incidence of adverse effect [42 days]
Adverse effects on hepatic function, renal function, and other adverse effects resulted from dressing application will be reported as "present" or "not present".
- Vancouver scar scale (VSS) [6 months]
Vancouver scar scale evaluated by clinician at 1, 3, and 6 months after complete wound healing
- Patient scale of Patient and observer scar scale (POSAS) [6 months]
Patient scale of Patient and observer scar scale (POSAS) evaluated by patients 6 months after complete wound healing
- Erythema level [6 months]
Erythema level measured by using Mexameter® at 1, 3, and 6 months after complete wound healing
- Melanin level [6 months]
Melanin level measured by using Mexameter® at 1, 3, and 6 months after complete wound healing
- Trans-epidermal water loss (TEWL) [6 months]
TEWL measured by using Tewameter® at 1, 3, and 6 months after complete wound healing
- Skin hydration [6 months]
Hydration level measured by using Corneometer® at 1, 3, and 6 months after complete wound healing
- Skin elasticity [6 months]
Elasticity parameters measured by using Cutometer® at 1, 3, and 6 months after complete wound healing
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients who have STSG donor site wounds on the thigh area
-
Age more than 18 years old
-
The split-thickness skin graft is harvested for the first time at the investigated area.
-
Patients who are able to communicate with the Thai language
-
Willingness to participate
Exclusion Criteria:
-
Patient with a mental disorder or immunocompromised diseases
-
Patients who cannot or not willing to follow the protocol
-
Known sensitivity or allergy to sericin, chlorhexidine, and collagen
-
Pregnancy or lactation
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Chulalongkorn Hospital | Bangkok | Thailand | 10330 |
Sponsors and Collaborators
- Chulalongkorn University
Investigators
- Principal Investigator: Pornanong Aramwit, Ph.D, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Med Chula IRB 143/63